• Silexion Therapeutics signed warrant inducement deal covering 1,995,092 existing warrants, with holders agreeing to exercise for cash at reduced exercise price of $0.5 per share.
• Transaction expected to generate about USD 1 million gross proceeds, with closing targeted around May 18, 2026.
• As consideration, company will issue unregistered Series C and Series D warrants to buy up to 3,990,184 ordinary shares at $0.5 per share, subject to shareholder approval.
• H.C. Wainwright to act as placement agent, earning 7% cash fee plus 1% management fee, with placement agent warrants for up to 139,656 ordinary shares at $0.625 per share.
• Company to file resale registration statement for shares underlying new warrants within 30 days, with net proceeds earmarked for general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-002739), on May 15, 2026, and is solely responsible for the information contained therein.